



**Figure S1.** Viability assays on HPV+ CU-OP-2 and CU-OP-20 with single inhibitors with and without irradiation. WST-1 viability assays on HPV+ CU-OP-2 and CU-OP-20 with viability measured as absorbance 24-72 h after single treatments with 0.5-1 μM BYL719 (A-D), BMN-673 (E-H) and MK-1775 (I-L), with/without 10 Gy. BYL denotes BYL719, BMN denotes BMN-673 and MK denotes MK-1775.



**Figure S2.** Combinational effects on HPV<sup>+</sup> CU-OP-2 and CU-OP-20 with single inhibitors and irradiation. Combinational effects on HPV<sup>+</sup> CU-OP-2 and CU-OP-20 upon adding 10 Gy to PI3K inhibitor BYL719, to PARP inhibitor BMN-673 and to WEE-1 inhibitor MK-1775 (**A-B**). Combination indexes (CIs) were shown with the highest single agent approach after 48 h (**A**) and 72 h (**B**), where CI < 1 shows a positive and CI > 1 a negative combination effect. CIs were calculated from the mean of three experiments analysed by WST-1 assays at 48 and 72 h after treatment. BYL denotes BYL719; and BMN denotes BMN-673 and MK denotes MK-1775.



**Figure S3.** Proliferation responses of HPV<sup>+</sup> CU-OP-2 and , CU-OP-20 cell lines with single inhibitors and irradiation. Proliferation responses sponses of HPV<sup>+</sup> CU-OP-2, CU-OP-3, CU-OP-20, and HPV<sup>-</sup> CU-OP-17 after treatment with PI3K inhibitor BYL719 (A–D) or with WEE1 inhibitor MK-1775 (E–H) with/without 10 Gy. The graphs represent one run per cell line. Confluence (%) denotes proliferation response; BYL denotes BYL719 and MK denotes MK-1775.